The Delhi High Court has dismissed Teva’s action to stop Hyderabad-based Natco Pharma from marketing a generic version of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).
The US Appeals Court for the Federal Circuit has affirmed a lower court decision that GlaxoSmithKline’s patent covering Avodart and Jalyn is valid, rejecting claims put forward by a group of generic drug makers.
The US District Court for the District of Maryland has ruled that Taiwanese company TWi Pharmaceuticals’ generic version of Par Pharmaceuticals’ Megace ES drug does not infringe US patent 7,101,576.
Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.
The US Court of Appeals for the Federal Circuit has upheld a patent covering Pfizer’s pain drug Lyrica, closing the market to any generic challengers until 2018.
The UK High Court has decided to award Slovenian generic pharmaceutical company KRKA damages after a preliminary injunction enforced against the company by AstraZeneca was discharged.
A government-appointed panel in India is preparing to evaluate more patented drugs for local generic pharmaceutical companies to mimic, according to reports.
Pharmaceutical company Novo Nordisk has left a group of pharmaceutical companies that are unhappy with proposed drug laws in South Africa.
On January 17, Actavis confirmed that the US District Court for the District of New Jersey found its US patent 7,704,984, which covers Lo Loestrin Fe birth control pills, to be valid and infringed by Lupin and Amneal.
Aurobindo’s European subsidiary is set to acquire Actavis’s commercial generic operations in seven Western European markets in a deal worth about €30 million ($40 million).